CliffBio
biologic

Hercessi

trastuzumab-strf

Loss of exclusivity—loss of exclusivity
CompanyAccord Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameHercessi
Active ingredienttrastuzumab-strf
Strength150MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2024
Marketing statusRx

More from Accord Biopharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Hercessi patent cliff — loss of exclusivity — | CliffBio